"This transaction demonstrates our ability to unlock unrecognized value in Nektar's legacy collaborations and access significant capital in a non-dilutive transaction. The proceeds from this sale will strengthen our cash position considerably and we are pleased to have Royalty Pharma as our partner in this transaction."

Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics

Approved applications

A novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease. This condition - which affects patients on dialysis, as well as subset of patients not on dialysis - occurs when kidney functions become impaired, primarily due to diabetes, high blood pressure or injury.

Therapeutic Area

Chronic Kidney Disease (CKD)

Acquisition Date

Feb 2012